Table 2 Treatments and clinical course of COVID-19 patients according to Herpesviridae status
From: Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients
All patients (n = 38) | No Herpesviridae reactivation (n = 20) | Herpesviridae reactivation (n = 18) | P value | |
|---|---|---|---|---|
Antibiotics | 38 (100) | 20 (100) | 18 (100) | 0.99 |
Antiviral | 32 (84) | 16 (80) | 16 (89) | 0.66 |
Steroids | 12 (32) | 4 (20) | 8 (44) | 0.16 |
ECMO | 3 (8) | 1 (5) | 2 (11) | 0.49 |
Duration of NMB infusion | 6 (3–11) | 5 (3–8) | 6 (3–11) | 0.73 |
Renal replacement therapy | 9 (24) | 5 (25) | 4 (22) | 0.99 |
Prone positioning ventilation | 21 (55) | 11 (52) | 10 (56) | 0.24 |
Duration of mechanical ventilation | 18 (13–25) | 9 (6–14) | 23 (18–39) | 0.0001 |
Ventilator-free days at day 28 | 8 (0–15) | 14 (7–20) | 2 (0–3) | 0.0008 |
Ratio of PaO2 to FiO2 on day 7 | 193 (135–248) | 212 (160–260) | 178 (135–195) | 0.04 |
Ratio of PaO2 to FiO2 on day 14 | 216 (174–308) | 280 (222–401) | 186 (114–233) | 0.01 |
SOFA score on day 7 | 7 (5–11) | 7 (5–10) | 10 (6–11) | 0.19 |
SOFA score on day 14 | 7 (2–10) | 3 (1–10) | 7 (2–10) | 0.39 |
Bacterial VAP | 9 (24) | 3 (15) | 6 (33) | 0.18 |
ICU length of stay | 23 (16–34) | 16 (12–24) | 29 (24–47) | 0.0001 |
Death in ICU | 4 (10.5) | 2 (10) | 2 (11) | 0.99 |